Effect a synthetic Aluminium-Magnesium Silicate (AMS) has on chloroquine was tested. Thirty, Plasmodium berghei-infected mice, in three experimental groups (7 mg/kg, 5 mg/kg and 3 mg/kg) of 10 mice each, were treated....Effect a synthetic Aluminium-Magnesium Silicate (AMS) has on chloroquine was tested. Thirty, Plasmodium berghei-infected mice, in three experimental groups (7 mg/kg, 5 mg/kg and 3 mg/kg) of 10 mice each, were treated. Two subgroups, in each experiment, were treated with chloroquine and with a chloroquine-AMS drug formulation, respectively. Five of the infected mice served as controls. Parasitaemia (%), Haemoglobin concentration (Hb), Red Blood Cells (RBC), rectal temperature and body weight were assessed. Parasitaemia of subgroups treated at 7 mg/kg were higher than that of the control. Also, at 7 mg/kg, there was mortality with chloroquine (20%) and with the chloroquine-AMS drug (80%). At 5 mg/kg and 3 mg/kg, the AMS significantly (P < 0.05) improved ability of chloroquine to reduce plamodial parasitaemia, from 2.46 ± 0.21 to 1.57 ± 0.25 and from 3.82 ± 0.06 to 2.12 ± 0.08. It also significantly (P < 0.05) improved means of Hb and RBC from 12.25 ± 0.27 and 88.99 ± 5.72 to 12.68 ± 0.18 and 92.91 ± 4.01 and from 10.18 ± 3.00 and 63.39 ± 18.02 to 12.98 ± 0.47 and 95.23 ± 5.32. Body weight increased at 5 mg/kg, from 29.06 ± 1.95 to 32.66 ± 2.10 kg (P < 0.05) while at 3 mg/kg, rectal temperature reduced from 37.35 ± 0.32 to 36.84oC ± 0.23oC (P < 0.05). These results suggest, AMS worsened chloroquine toxicity at 7 mg/kg but potentiated its antiplasmodial activities at the lower doses.展开更多
To investigate if Aluminium-Magnesium Silicate (AMS) could make drugs regain effects against resistant pathogens, its effect was tested on sulphadimidine against sulphadimidine-resistant Escherichia coli. Two groups o...To investigate if Aluminium-Magnesium Silicate (AMS) could make drugs regain effects against resistant pathogens, its effect was tested on sulphadimidine against sulphadimidine-resistant Escherichia coli. Two groups of chicks infected with sulphadimidine-resistant E. coli were treated at sulphadimidine dose rate of 1 g/litre of drinking water, with sulphadimidine and with an AMS-sulphadimidine drug formulation, respectively. Two other groups were similarly treated at sulphadimidine dose rate of 0.75 g/litre, while the fifth group served as control. Mean titres of the bacterium in bile of the chicks were compared. Titres, 119,200 ± 55,800 CFU/mL of the group treated with sulphadimidine at rate of 1 g/ litre and 14,800 ± 1700 CFU/mL of the group treated at rate of 0.75 g/litre, did not vary from 33,200 ± 5200 CFU/mL of the control (P > 0.05) but 295,200 ± 106,400 CFU/ml of the group treated at rate of 1 g/litre, with the AMS-sulpha- dimidine drug was significantly (P < 0.05) higher than that of the control while 5200 ± 1400 CFU/mL of the group treated at dose of 0.75 g/litre, with the AMS-sulphadimidine drug, reduced significantly (P < 0.05).展开更多
Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal...Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal amount of a synthetic AMS on a volume to weight [v/w] basis, for one hour and then centrifuged. Viral titres of the supernatants were tested by the haemagglutination [HA] test and their mean titre compared with mean titre of portions of same viral samples, not incubated with the AMS. Also, five puppies and five adult dogs infected with the parvovirus isolates were treated by dosing each with 400 mg/kg of a drug formulation that has 12% AMS per os for seven days. As control, five puppies and five adult dogs from same class as the experimental dogs were similarly infected but were not treated. Incubating parvovirus with AMS reduced its load from mean HA titre 825.6 ± 261.1 to mean HA, 270.8 ± 132.1 [p < 0.05]. Also treating parvovirus infected dogs with a 12% AMS drug formulation reduced mortality due to the virus from 100% to zero [p < 0.01].展开更多
Effects a synthetic Aluminium-Magnesium Silicate [AMS] has on Avian Influenza Virus (AIV) were tested. Equal amounts of AIV samples and of the AMS were mixed, kept one hour at room temperature before centrifuging. The...Effects a synthetic Aluminium-Magnesium Silicate [AMS] has on Avian Influenza Virus (AIV) were tested. Equal amounts of AIV samples and of the AMS were mixed, kept one hour at room temperature before centrifuging. The supernatants were remeasured and tested for, viral titre, Mean Death Time (MDT) and Mortality Rate of chicken Embryos (EMR). Volumes of the viral samples reduced at rate of 23.4% ± 5.48%. Viral titres reduced significantly (P < 0.01) from HA, 73 ± 32.72 to 1.4 ± 0.43. Also, EMR of infected chicken embryos reduced from 100% to 65%, while MDT of those that died,increased significantly (P < 0.01) from 76 ± 4.38 to 136 ±18.93 hours. When incubation with AMS was repeated on portions of an AIV sample, MDT increased from 64 to 104 hours with the portion incubated once. AIV portions on which incubation with AMS was repeated could not kill chicken embryos.展开更多
To test effect of a synthetic Aluminium-Magnesium Silicate (AMS) on anthelmintic efficacy of piperazine citrate (PC), 35 mice were infected by dosing each, 0.15 ml Helignosomoides bakeri sample which contained 200 inf...To test effect of a synthetic Aluminium-Magnesium Silicate (AMS) on anthelmintic efficacy of piperazine citrate (PC), 35 mice were infected by dosing each, 0.15 ml Helignosomoides bakeri sample which contained 200 infective larvae, per os. Following comfirmation of establishment of infection by faecal floatation, they were assigned into seven groups of 5 each, and were treated with piperazine citrate, per os, at rates of 110 mg/kg (PC), 110 mg/kg (PC in AMS), 82.5 mg/kg (PC), 82.5 mg/kg (PC in AMS), 55 mg/kg (PC) and 55 mg/kg (PC in AMS) respectively. The seventh group served as untreated control. Mean Eggs Per Gramm of faeces (EPG) were 375 ± 32.27, 175 ± 14.43, 830 ± 1.04, 70 ± 12.25, 850 ± 293.06, 370 ± 58.54 and 2,200 ± 2.55 respectively. This showed EPG reduction rates of 83%, 92%, 62%, 97%, 61% and 83% among the respective treated groups.展开更多
To test if stabilizing Ampicillin trihydrate (AT) with Aluminium-Magnesium Silicate (AMS) can enhance its antibacterial activities, different concentrations of AT solution and of a formulation of AT in the AMS, were m...To test if stabilizing Ampicillin trihydrate (AT) with Aluminium-Magnesium Silicate (AMS) can enhance its antibacterial activities, different concentrations of AT solution and of a formulation of AT in the AMS, were made and used for sensitivity test on Salmonella gallinarum cultures. Also, S. gallinarum-infected chicks were treated with;10 mg/Kg (AT), 10 mg/Kg (AT in AMS), 7.5 mg/Kg (AT), 7.5 mg/Kg (AT in AMS). Mean diameter of inhibition zone, 28.39 ± 2.07 mm produced by AT did not vary significantly (P > 0.05) from 26.36 ± 2.05 mm produced by AT in AMS. However, mean Salmonella gallinarum culture forming units per ml of bile, 17.6 ± 11 × 105of the untreated chicks and 3.4 ± 0.81 × 105(80.58% reduction), 2.4 ± 0.67 × 105(85.70% reduction), 5.4 ± 1.93 × 105(69.20% reduction ) and 0.38 ± 0.13 × 105(97.80% reduction ) of the respective treated groups, showed AMS significantly (P S. gallinarum infection, in vivo.展开更多
文摘Effect a synthetic Aluminium-Magnesium Silicate (AMS) has on chloroquine was tested. Thirty, Plasmodium berghei-infected mice, in three experimental groups (7 mg/kg, 5 mg/kg and 3 mg/kg) of 10 mice each, were treated. Two subgroups, in each experiment, were treated with chloroquine and with a chloroquine-AMS drug formulation, respectively. Five of the infected mice served as controls. Parasitaemia (%), Haemoglobin concentration (Hb), Red Blood Cells (RBC), rectal temperature and body weight were assessed. Parasitaemia of subgroups treated at 7 mg/kg were higher than that of the control. Also, at 7 mg/kg, there was mortality with chloroquine (20%) and with the chloroquine-AMS drug (80%). At 5 mg/kg and 3 mg/kg, the AMS significantly (P < 0.05) improved ability of chloroquine to reduce plamodial parasitaemia, from 2.46 ± 0.21 to 1.57 ± 0.25 and from 3.82 ± 0.06 to 2.12 ± 0.08. It also significantly (P < 0.05) improved means of Hb and RBC from 12.25 ± 0.27 and 88.99 ± 5.72 to 12.68 ± 0.18 and 92.91 ± 4.01 and from 10.18 ± 3.00 and 63.39 ± 18.02 to 12.98 ± 0.47 and 95.23 ± 5.32. Body weight increased at 5 mg/kg, from 29.06 ± 1.95 to 32.66 ± 2.10 kg (P < 0.05) while at 3 mg/kg, rectal temperature reduced from 37.35 ± 0.32 to 36.84oC ± 0.23oC (P < 0.05). These results suggest, AMS worsened chloroquine toxicity at 7 mg/kg but potentiated its antiplasmodial activities at the lower doses.
文摘To investigate if Aluminium-Magnesium Silicate (AMS) could make drugs regain effects against resistant pathogens, its effect was tested on sulphadimidine against sulphadimidine-resistant Escherichia coli. Two groups of chicks infected with sulphadimidine-resistant E. coli were treated at sulphadimidine dose rate of 1 g/litre of drinking water, with sulphadimidine and with an AMS-sulphadimidine drug formulation, respectively. Two other groups were similarly treated at sulphadimidine dose rate of 0.75 g/litre, while the fifth group served as control. Mean titres of the bacterium in bile of the chicks were compared. Titres, 119,200 ± 55,800 CFU/mL of the group treated with sulphadimidine at rate of 1 g/ litre and 14,800 ± 1700 CFU/mL of the group treated at rate of 0.75 g/litre, did not vary from 33,200 ± 5200 CFU/mL of the control (P > 0.05) but 295,200 ± 106,400 CFU/ml of the group treated at rate of 1 g/litre, with the AMS-sulpha- dimidine drug was significantly (P < 0.05) higher than that of the control while 5200 ± 1400 CFU/mL of the group treated at dose of 0.75 g/litre, with the AMS-sulphadimidine drug, reduced significantly (P < 0.05).
文摘Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal amount of a synthetic AMS on a volume to weight [v/w] basis, for one hour and then centrifuged. Viral titres of the supernatants were tested by the haemagglutination [HA] test and their mean titre compared with mean titre of portions of same viral samples, not incubated with the AMS. Also, five puppies and five adult dogs infected with the parvovirus isolates were treated by dosing each with 400 mg/kg of a drug formulation that has 12% AMS per os for seven days. As control, five puppies and five adult dogs from same class as the experimental dogs were similarly infected but were not treated. Incubating parvovirus with AMS reduced its load from mean HA titre 825.6 ± 261.1 to mean HA, 270.8 ± 132.1 [p < 0.05]. Also treating parvovirus infected dogs with a 12% AMS drug formulation reduced mortality due to the virus from 100% to zero [p < 0.01].
文摘Effects a synthetic Aluminium-Magnesium Silicate [AMS] has on Avian Influenza Virus (AIV) were tested. Equal amounts of AIV samples and of the AMS were mixed, kept one hour at room temperature before centrifuging. The supernatants were remeasured and tested for, viral titre, Mean Death Time (MDT) and Mortality Rate of chicken Embryos (EMR). Volumes of the viral samples reduced at rate of 23.4% ± 5.48%. Viral titres reduced significantly (P < 0.01) from HA, 73 ± 32.72 to 1.4 ± 0.43. Also, EMR of infected chicken embryos reduced from 100% to 65%, while MDT of those that died,increased significantly (P < 0.01) from 76 ± 4.38 to 136 ±18.93 hours. When incubation with AMS was repeated on portions of an AIV sample, MDT increased from 64 to 104 hours with the portion incubated once. AIV portions on which incubation with AMS was repeated could not kill chicken embryos.
文摘To test effect of a synthetic Aluminium-Magnesium Silicate (AMS) on anthelmintic efficacy of piperazine citrate (PC), 35 mice were infected by dosing each, 0.15 ml Helignosomoides bakeri sample which contained 200 infective larvae, per os. Following comfirmation of establishment of infection by faecal floatation, they were assigned into seven groups of 5 each, and were treated with piperazine citrate, per os, at rates of 110 mg/kg (PC), 110 mg/kg (PC in AMS), 82.5 mg/kg (PC), 82.5 mg/kg (PC in AMS), 55 mg/kg (PC) and 55 mg/kg (PC in AMS) respectively. The seventh group served as untreated control. Mean Eggs Per Gramm of faeces (EPG) were 375 ± 32.27, 175 ± 14.43, 830 ± 1.04, 70 ± 12.25, 850 ± 293.06, 370 ± 58.54 and 2,200 ± 2.55 respectively. This showed EPG reduction rates of 83%, 92%, 62%, 97%, 61% and 83% among the respective treated groups.
文摘To test if stabilizing Ampicillin trihydrate (AT) with Aluminium-Magnesium Silicate (AMS) can enhance its antibacterial activities, different concentrations of AT solution and of a formulation of AT in the AMS, were made and used for sensitivity test on Salmonella gallinarum cultures. Also, S. gallinarum-infected chicks were treated with;10 mg/Kg (AT), 10 mg/Kg (AT in AMS), 7.5 mg/Kg (AT), 7.5 mg/Kg (AT in AMS). Mean diameter of inhibition zone, 28.39 ± 2.07 mm produced by AT did not vary significantly (P > 0.05) from 26.36 ± 2.05 mm produced by AT in AMS. However, mean Salmonella gallinarum culture forming units per ml of bile, 17.6 ± 11 × 105of the untreated chicks and 3.4 ± 0.81 × 105(80.58% reduction), 2.4 ± 0.67 × 105(85.70% reduction), 5.4 ± 1.93 × 105(69.20% reduction ) and 0.38 ± 0.13 × 105(97.80% reduction ) of the respective treated groups, showed AMS significantly (P S. gallinarum infection, in vivo.
